Chikungunya vaccine is linked to severe complications in older adults Live virus vaccine caused hospitalizations and two ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

Six of the reports have been in the U.S. About 80,000 doses of Ixchiq have been distributed globally and the CDC said the most serious issues have been in people with underlying chronic conditions.

The FDA stated that 17 serious adverse events, including two deaths, have been reported in recipients of the vaccine IXCHIQ over the age of 60 worldwide. "CDC and FDA recently investigated five ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine. The FDA and the Centers for Disease ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths. About 80,000 Ixchiq doses ...

Healthcare providers should pause in their use of the chikungunya live vaccine (Ixchiq) while investigation ... for Disease Control and Prevention (CDC). A total of 17 serious adverse events ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.